PLA 2G15 inhibitor - Scenic Biotech
Alternative Names: PLA-2G15Latest Information Update: 30 May 2025
At a glance
- Originator Scenic Biotech
- Class Antidementias; Neuroprotectants; Small molecules
- Mechanism of Action Phospholipase A2 group XV inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Frontotemporal dementia; Neuronal ceroid lipofuscinosis; Niemann-Pick disease type C
Most Recent Events
- 07 May 2025 Preclinical trials in Frontotemporal dementia in Netherlands (Parenteral), before May 2025 (Scenic Biotech pipeline May 2025)
- 07 May 2025 Preclinical trials in Neuronal ceroid lipofuscinosis in Netherlands (Parenteral), before May 2025 (Scenic Biotech pipeline May 2025)
- 07 May 2025 Preclinical trials in Niemann-Pick disease type C in Netherlands (Parenteral), before May 2025 (Scenic Biotech pipeline May 2025)